We would like to mention that in our study we used the older 200754 WHO classification instead of the one from 2016 or 202155,56, which considers grade 2 and 3 gliomas as part of the same spectrum for which molecular markers (e.g., IDH, 1p/19q, TERT promoter and EGFR amplification) are of particular relevance. The gene discussed is IDH1; the disease is central nervous system cancer.